NEW YORK (GenomeWeb News) – Hepregen and The Hamner Institutes for Health Sciences today announced a deal aimed at research to be conducted by the two partners.
Under the terms of the agreement, the two entities will carry out R&D work directed at defining the basic concepts "regarding the potential for new microliver products," and new applications and assay methods for Hepregen's existing microliver products.
The research will be led by Edward LeCluyse, associate investigator at Hamner, and Jack McGeehan, Hepregen's VP of Operations.
Financial and other terms of the deal were not disclosed.
Medford, Mass.-based Hepregen develops bioengineered microliver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic, and diagnostic product development. The company was spun out by Battelle Ventures in 2009.
Hamner, headquartered in Research Triangle Park, N.C., is a non-profit translational biomedical research institute.